ABSTRACT
Efecto del Clopidogrel con o sin Omeprazol en Pacientes con Stent en la Arteria Carótida

INTRODUCTION
Percutaneous carotid artery stenting (CAS) for stenoses of the internal carotid artery (ICA) has the potential of being minimally invasive, less traumatic and safer in patients with high surgical risk than carotid endarterectomy (1, 2) . Carotid artery stenting provides a safe and reasonable revascularization alternative in patients with symptomatic carotid artery disease. The main complications after stent placement are thrombus and restenosis of the stented artery, which may require revascularization procedures. In-stent restenosis (ISR) continues to be a concern, with angiographic and clinical restenosis rates reported to be 10−15% (3, 4) . Several factors have been associated with an increased risk of restenosis, including long and multiple stents, stent malapposition and lack of dual antiplatelet drugs. Furthermore, the embolization of plaque fragments has generated concern regarding the safety and wisdom of CAS and transcranial Doppler (TCD) studies have indicated the occurrence of emboli associated with CAS (5). Antithrombotic drugs are used during the acute management of carotid intervention. In patients with carotid artery stents, aspirin and clopidogrel, dual antiplatelet treatment, is prescribed to reduce the risks of thromboemboli and in-stent restenosis. The risks of antiplatelet drugs are associated with gastrointestinal haemorrhage which is the most common serious bleeding complication from the use of long-term antiplatelet therapy (6, 7) . Proton pump inhibitors (PPIs) have been advocated to reduce the gastrointestinal haemorrhage risk in CAS patients with oral dual antiplatelet, aspirin and clopidogrel (8, 9) . Recent studies have shown inhibition of the antiplatelet effect of clopidogrel by PPIs most consistently (10, 11) . Therefore, some studies believe the combination of antiplatelet and PPIs could lead to the risk of adverse cardiovascular accident (12, 13) . In this study, we observed the effect of clopidogrel plus aspirin with or without omeprazole in patients with carotid stenoses after they received carotid stenting placement and assessed the efficacy and safety of concomitant administration of clopidogrel and omeprazole in CAS patients.
SUBJECTS AND METHODS
The study population consisted of 64 patients with CAS who were managed in the Department of Neurology in the Affiliated Hospital of Ningxia Medical University from January 2009 to March 2011. The average age was 55.16 ± 8.38 years; 68% was male. All enrolled patients underwent the C 13 urea breath test (C 13 UBT) to detect Helicobacter pylori before CAS. Patients with positive infection were advised to undergo H pylori eradication therapy and all agreed. The patients who had H pylori infection and history of peptic ulcer were assigned to take dual antiplatelets (clopidogrel 75 mg/daily and enteric-coated aspirin 100 mg/daily) with omeprazole 20 mg/daily. The patients who had no H pylori infection were only assigned to take dual antiplatelets (clopidogrel 75 mg/daily and enteric-coated aspirin 100 mg/daily). Clinical follow-up was conducted at three months and six months. All patients underwent TCD to observe the middle cerebral artery (MCA) and ultrasound to observe the carotid artery. In the omeprazole group, one patient underwent computed tomography angiography (CTA) and TCD at six months after CAS, one patient underwent digital subtraction angiography (DSA) and TCD at six months after CAS. All patients gave written informed consent, and the study protocol was approved by the hospital ethics committee and the Ningxia committee on research ethics for the protection of human subjects.
Quantitative variables are described as mean ± SD. Categorical variables are presented as numbers and percentages. Comparisons of quantitative variables were performed by independent-sample t-test analysis for normally distributed variables. SPSS 15.0 package programme (SPSS, Chicago, IL, USA) was used for data analysis. A probability value of < 0.05 was considered to indicate statistical significance.
RESULTS
Seven patients did not continue follow-up for personal reasons. Twenty-three patients had H pylori infection by C 13 UBT. There were 26 in the clopidogrel and aspirin group with omeprazole (23 patients had H pylori infection, five patients had history of peptic ulcer, two patients had both H pylori infection and history of peptic ulcer) and 31 in the clopidogrel and aspirin group without omeprazole. The two study groups were well matched with respect to baseline characteristics. There were eight gastrointestinal bleeding events: melaena and positive fecal occult blood were present in these patients. There was also a significant reduction in the number of patients with investigator-defined gastrointestinal bleeding events with omeprazole (26 patients) as compared without omeprazole (Fig. 1) .
Fifty-seven patients underwent TCD at three months and six months after CAS. We used mean velocity (MV) and Fig. 4 ]. omeprazole. One patient underwent DSA and TCD at six months after CAS (Fig. 3 ) without omeprazole. From CTA Fifty-seven patients underwent ultrasound at three months and six months after CAS. We used peak systolic velocity (PSV) to assess the internal carotid artery (ICA). We did not observe apparent thrombus in the carotid artery. At the same time, there was no statistical significance in these two groups by ultrasound (p > 0.05), [ Table 2 , Fig. 5 ].
DISCUSSION
A meta-analysis of five randomized clinical trials demonstrated that combination therapy with aspirin plus clopidogrel is associated with reductions in all-cause and cardiovascular mortality in patients who present with ST-segment elevation myocardial infarction as well as modest reductions in myocardial infarction or stroke in patients (14) . Therefore, clopidogrel has become the second most commonly used prescription drug worldwide (15, 16) . Clopidogrel alone, aspirin alone, and their combination are all associated with increased risk of gastrointestinal bleeding (17) . The risk of gastrointestinal bleeding is increased in people taking dual antiplatelet drugs. Bleeding can occur at any site in the gastrointestinal tract, but it is most common in the upper gastrointestinal tract. A large case-control study to evaluate upper gastrointestinal bleeding in patients using single and dual antiplatelet drugs in the Danish population found an odds ratio for bleeding of 1.8 in people taking low dose aspirin alone, 1.1 in those taking clopidogrel alone and 7.4 in those taking both (18) . Gastrointestinal bleeding was an important correlate of premature antiplatelet therapy cessation, and 20.8% of patients with gastrointestinal bleeding were discharged without aspirin or thienopyridine therapy (19) . Patients who had gastrointestinal bleeding usually presented with vomiting blood, passing dark tarry stools or melaena, upper abdominal symptoms and postural dizziness. In this study, patients presented with only melaena. Clinical characteristics that increase the risk of gastrointestinal bleeding include advanced age, concurrent use of anticoagulants, steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, and H pylori infection. A history of peptic ulcer disease was an independent predictor of risk for gastrointestinal bleeding in patients treated with dual antiplatelet therapy (20) . Longer term risks were related to oral dual antiplatelets, usually aspirin and clopidogrel. Increased dose and duration of dual antiplatelet treatment are also likely to affect the risk of upper gastrointestinal bleeding. The risk of gastrointestinal bleeding increases as the number of risk factors increase (17) .
Studies have shown that platelet aggregation and blood coagulation are optimal at pH 7.4. Below pH 5.9, platelet aggregation, the initial step of haemostasis, is practically non-existent (21) . Only PPIs can reliably achieve such values if sufficient doses are given. Guidelines recommend that patients taking dual antiplatelet drugs who are at high risk of upper gastrointestinal bleeding (as outlined above) should be co-prescribed PPIs, because of their considerable gastroprotective effect. Proton pump inhibitors should be continuously available in the circulation to inhibit newly generated pumps and thereby inhibit gastric acidity for prolonged periods. Therefore, PPIs play an important role in treatment of gastrointestinal bleeding. This study also showed a significant reduction in the risk of gastrointestinal clinical events, including overt upper gastrointestinal bleeding, in patients receiving dual antiplatelet therapy who also received omeprazole. Clopidogrel is a prodrug, which requires conversion by the liver primarily via CYP3A4 and CYP2C19 to an active metabolite, which irreversibly binds to the platelet adenosine diphosphate receptor, thereby inhibiting platelet aggregation (22, 23) . Proton pump inhibitors are metabolized by the hepatic cytochrome P-450 system, predominantly CYP2C19 (24) . The major site of drug-drug interaction between clopidogrel and PPIs appears to involve the CYP2C19 isoenzyme pathway. Concomitant use of PPIs may competitively inhibit activation of clopidogrel by CYP2C19, thereby attenuating its antiplatelet effect.
Transcranial Doppler may be used by clinicians as a noninvasive screening tool for the diagnosis of intracranial arterial stenosis. Data regarding the sensitivity and specificity of TCD in the diagnosis of MCA have been published. Ultrasound is noninvasive, rapid and relatively inexpensive and should be an excellent modality for the assessment of results after placement of a carotid artery stent. In this study, we used TCD and ultrasound to assess carotid artery and MCA after the carotid artery stent placement. We assigned patients, who had H pylori infection and a history of peptic ulcer, to receive dual antiplatelet with omeprazole. The result that patients receiving omeprazole with clopidogrel plus aspirin had no more thromboemboli and carotid artery stent restenosis than those receiving clopidogel plus aspirin alone suggests that the potential interaction between omeprazole and clopidogrel is safe. There was no significant difference in tone and the distribution and appearance of the spectrum of TCD in these two groups with or without omeprazole. The results of TCD showed that MV and PI of the MCA were not After all, small pharmacodynamic studies have indicated a potential influence of PPIs on the antiplatelet effects of clopidogrel. As the plasma half-lives of both clopidogrel and omeprazole are short (1−2 hours), the potential for drugdrug competition at either the P-glycoprotein or CYP2C19 level may be attenuated by separating the timing of clopidogrel and omeprazole administration (25) . Therefore, we suggest that "dose separation" strategy may diminish advantage during the co-administration of clopidogrel and omeprazole.
In conclusion, patients with carotid artery stent placement who were receiving dual antiplatelet therapy had a significant reduction in gastrointestinal bleeding with omeprazole use as compared without omeprazole. Furthermore, our small, single-centre study suggests that there was no effect of concomitant use of omeprazole and clopidogrel on antiplatelet inhibition. Concomitant use of omeprazole in patients who were receiving dual antiplatelet aspirin and clopidogrel after CAS is safe and feasible.
